Recently, BRAF inhibitors (iBRAF), such as vemurafenib, dabrafenib and encorafenib, have revolutionized the treatment of BRAF V600E metastatic melanoma in monotherapy or in combination with other drugs [57,58,59]. This evidence concerns the gene BRAF and metastatic melanoma.